SARS‐CoV‐2 vaccines are not free of neurological side effects

Finsterer, Josef; Scorza, Fúlvio A.

doi:10.1111/ane.13451

Cited by 33 publications

(27 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether the number of patients with SARS-CoV-2 associated GBS has been declined since the introduction of SARS-CoV-2 vaccines is unknown. Nevertheless, SARS-CoV-2 vaccines are not free from side effects and may not only cause mild or moderate adverse reactions but even severe complications, including neurological side effects (2). Though generally rare, these neurological side effects are increasingly recognized and reported, including SARS-CoV-2 vaccination associated GBS (SCoVaG).…”

Section: ' Introductionmentioning

confidence: 99%

Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients

Finsterer¹,

Scorza²,

Scorza³

2021

Clinics

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 vaccinations are not free from side effects. Usually, they are mild or moderate but occasionally severe. One of these severe side effects is Guillain-Barre ´syndrome (GBS). This review summarizes and discusses GBS as a side effect of SARS-CoV-2 vaccinations (SCoVaG) based on recent research reports. Altogether, nine articles reporting 18 patients with SCoVaG were identified and one more report on another patient is under review. The age for the studies ranged between 20-86y. Nine patients were male, and ten were female. In all 19 patients, SCoVaG developed after the first dose of the vaccine. The Astra Zeneca vaccine was used in fourteen patients, the Pfizer vaccine in four patients, and the Johnson & Johnson vaccine was applied in one patient. The latency between vaccination and onset of GBS ranged from 3h to 39d. The treatment of SCoVaG included IVIGs (n=13), steroids (n=3), or no therapy (n=3). Six patients required mechanical ventilation. Only a single patient recovered completely and partial recovery was achieved in nine patients. In conclusion, GBS may develop time-linked to the first dose of a SARS-CoV-2 vaccination. Though a causal relationship between SARS-CoV-2 vaccinations and SCoVaG remains speculative, more evidence is in favour than against it.

show abstract

Section: ' Introductionmentioning

confidence: 99%

Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients

Finsterer¹,

Scorza²,

Scorza³

2021

Clinics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Vaccines have also been reported as a potential cause of transverse myelitis [19,20]. Other case reports involving transverse myelitis due to administration of COVID-19 vaccines exhibit almost similar symptoms and results [21][22][23][24][25]. Malhotra et al reported their first case of transverse myelitis as an adverse event following the administration of AstraZeneca/Oxford (viral-vectored, recombinant ChAdOX1) COVID-19 vaccine [24].…”

Section: Discussionmentioning

confidence: 97%

Acute inflammatory Transverse Myelitis post Pfizer-BioNTech-COVID-19 vaccine in 16-year-old

Albokhari

Alsawas

Adnan

et al. 2021

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) originated in China in early March 2019. Saudi Food and Drug Authorityapproved the registration of the Pfizer-BioNTech COVID-19 vaccine in Saudi Arabia on December 10, 2020 and on May 10, 2021, Pfizer-BioNTech was given an authorized emergency use in 12 to 15 years old children. Saudi Arabia’s Ministry of Health started Pfizer-BioNTech COVID-19 vaccination for 12 to 18 years old on June 27, 2021. Here we have a case of 16-year-old female admitted to the medical ward diagnosed with acute inflammatory transverse myelitis after two weeks from second dose of the Pfizer-BioNTech COVID-19 vaccine. The diagnosis was based on normal laboratory workup but significant radiological findings. She was discharged after a full recovery.There are multiple cases of post-vaccine acute inflammatory transverse myelitisshared by medical journals, but due to lack of literature review for the teenager population, we think our case may be the first case of acute inflammatory transverse myelitis following second dose of Pfizer-BioNTech COVID-19 vaccine in this population.

show abstract

“…There have been reports of neurological adverse events following vaccination, such as cerebral venous sinus thrombosis and demyelinating episodes [ 21 ]. Only isolated cases of neurological events were reported in the clinical trials of major SARS-CoV-2 vaccines [ 22 ]. Finsterer et al reported several cases with neurological problems, and it seemed possible that the neurological problems were caused by a recent SARS-CoV-2 vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…An ischemic cerebellar stroke occurred four days after the first dose of a vector-based SARS-CoV-2 vaccination in a 29-year-old woman. A relapsed GBS experienced in a 32-year-old man eight days after receiving the first dose of a vector-based SARS-CoV-2 vaccination [ 22 ]. At least 19 patients with SARS-CoV-2 vaccination associated GBS have been reported as per the end of June 2021 [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…At least 19 patients with SARS-CoV-2 vaccination associated GBS have been reported as per the end of June 2021 [ 23 ]. According to data from the mRNA vaccine clinical trials, 7 out of 37,000 vaccination recipients got Bell's palsy [ 22 ]. Repajic et al report a case with three previous bouts of Bell's Palsy developed left sided Bell's Palsy less than 36 hours after receiving the second dose of the Pfizer-BioNTech COVID-19 Vaccine [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation